Hansa Biopharma Interim Report January-June 2019 |
| July 18, 2019 | July 2019 Bond Updates |
|
MALMÖ, Sweden, July 18, 2019 /PRNewswire/ -- Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues. Highlights for the second quarter 2019 - At the 2019 American Transplant... |
| View more at: https://www.prnewswire.com:443/news-releases/hansa-biopharma-interim-report-januaryjune-2019-300887235.html |
| Related News |
|